Cellular Solutions For Post-Viral Syndrome
A Pharmaceutical Solution Targeting Long Covid
A Pharmaceutical Solution Targeting Long Covid
Long Covid manifests as lethargy, pain, and persistent foggy brain.
Long Covid is reducing the quality of life for hundreds of millions of people globally. More Americans suffer from Long Covid than from cancer.
Billions of dollars are being spent to assess the issues and treatment for Long Covid. There are limited treatment options, and these can have serious side effects.
STIR Pharma has a potential, patented solution to treat Long Covid; STIR-101.
STIR-101 helps to return the overactive immune system to normal. It targets chronic fatigue primarily, and also respiratory and gut health function.
STIR-101 is not an anti-inflammatory but an immune modulator which also inhibits latent viral replication.
STIR-101 has completed preclinical toxicology and efficacy testing and successful Phase 1 and Phase 2A clinical trials, and has recently commenced a Phase 2 clinical trial.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.